drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous T cells genetically engineered to express a chimeric antigen receptor targeting carcinoembryonic antigen (CEA/CEACAM5), administered intravenously or intraperitoneally to recognize and kill CEA-positive tumor cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous, Intraperitoneal
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor that binds carcinoembryonic antigen (CEA/CEACAM5) on tumor cells. CAR engagement triggers CD3ΞΆ (with costimulatory domains) signaling to activate and expand the T cells, resulting in cytokine release and perforin/granzyme-mediated killing of CEA-positive cancer cells.
drug_name
CEA-targeted CAR-T cells
nct_id_drug_ref
NCT06126406